$488 Million is the total value of Bellevue Group AG's 122 reported holdings in Q4 2016. The portfolio turnover from Q3 2016 to Q4 2016 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| AMGN | AMGEN INC | $12,209,000 | -12.3% | 83,500 | 0.0% | 2.50% | -0.7% | |
| JAZZ | JAZZ PHARMACEUTICALS PLC | $9,137,000 | -10.2% | 83,800 | 0.0% | 1.87% | +1.7% | |
| MYL | MYLAN N V | $8,992,000 | +0.1% | 235,700 | 0.0% | 1.84% | +13.4% | |
| BAX | BAXTER INTL INC | $8,425,000 | -6.8% | 190,000 | 0.0% | 1.72% | +5.6% | |
| AGN | ALLERGAN PLC | $6,174,000 | -8.8% | 29,400 | 0.0% | 1.26% | +3.4% | |
| ALXN | ALEXION PHARMACEUTICALS INC | $6,044,000 | -0.1% | 49,400 | 0.0% | 1.24% | +13.2% | |
| BMRN | BIOMARIN PHARMACEUTICAL INC | $5,385,000 | -10.5% | 65,000 | 0.0% | 1.10% | +1.5% | |
| CERN | CERNER CORP | $4,666,000 | -23.3% | 98,500 | 0.0% | 0.96% | -13.0% | |
| MNKKQ | MALLINCKRODT PUB LTD CO | $4,025,000 | -28.6% | 80,800 | 0.0% | 0.82% | -19.1% | |
| ESRX | EXPRESS SCRIPTS HLDG CO | $3,405,000 | -2.5% | 49,500 | 0.0% | 0.70% | +10.5% | |
| MCK | MCKESSON CORP | $3,371,000 | -15.8% | 24,000 | 0.0% | 0.69% | -4.6% | |
| HALO | HALOZYME THERAPEUTICS INC | $3,142,000 | -18.2% | 318,000 | 0.0% | 0.64% | -7.3% | |
| RARE | ULTRAGENYX PHARMACEUTICAL INC | $3,023,000 | -0.9% | 43,000 | 0.0% | 0.62% | +12.3% | |
| ANTM | ANTHEM INC | $2,962,000 | +14.8% | 20,600 | 0.0% | 0.61% | +30.3% | |
| ZLTQ | ZELTIQ AESTHETICS INC | $2,611,000 | +11.0% | 60,000 | 0.0% | 0.54% | +25.9% | |
| LLY | LILLY ELI & CO | $2,574,000 | -8.4% | 35,000 | 0.0% | 0.53% | +3.7% | |
| QGEN | QIAGEN NV | $2,564,000 | +2.1% | 91,500 | 0.0% | 0.52% | +15.6% | |
| EARS | AURIS MED HLDG AG | $2,321,000 | -38.2% | 2,169,625 | 0.0% | 0.48% | -29.9% | |
| NKTR | NEKTAR THERAPEUTICS | $2,282,000 | -28.6% | 186,000 | 0.0% | 0.47% | -19.1% | |
| SGEN | SEATTLE GENETICS INC | $2,269,000 | -2.3% | 43,000 | 0.0% | 0.46% | +10.7% | |
| TMO | THERMO FISHER SCIENTIFIC INC | $2,258,000 | -11.3% | 16,000 | 0.0% | 0.46% | +0.4% | |
| GMED | GLOBUS MED INCcl a | $2,176,000 | +10.0% | 87,700 | 0.0% | 0.45% | +24.6% | |
| AET | AETNA INC NEW | $2,034,000 | +7.4% | 16,400 | 0.0% | 0.42% | +21.9% | |
| PRTA | PROTHENA CORP PLC | $2,017,000 | -18.0% | 41,000 | 0.0% | 0.41% | -7.0% | |
| AGIO | AGIOS PHARMACEUTICALS INC | $1,878,000 | -21.0% | 45,000 | 0.0% | 0.38% | -10.3% | |
| BLUE | BLUEBIRD BIO INC | $1,789,000 | -9.0% | 29,000 | 0.0% | 0.37% | +3.1% | |
| MGNX | MACROGENICS INC | $1,697,000 | -31.7% | 83,000 | 0.0% | 0.35% | -22.5% | |
| NVDQ | NOVADAQ TECHNOLOGIES INC | $1,631,000 | -38.7% | 230,000 | 0.0% | 0.33% | -30.6% | |
| PFE | PFIZER INC | $1,624,000 | -4.1% | 50,000 | 0.0% | 0.33% | +8.8% | |
| HCSG | HEALTHCARE SVCS GRP INC | $1,492,000 | -1.1% | 38,100 | 0.0% | 0.31% | +12.5% | |
| BMY | BRISTOL MYERS SQUIBB CO | $1,344,000 | +8.4% | 23,000 | 0.0% | 0.28% | +22.8% | |
| ACAD | ACADIA PHARMACEUTICALS INC | $1,298,000 | -9.3% | 45,000 | 0.0% | 0.27% | +2.7% | |
| INO | INOVIO PHARMACEUTICALS INC | $1,076,000 | -25.5% | 155,000 | 0.0% | 0.22% | -15.7% | |
| INSYQ | INSYS THERAPEUTICS INC NEW | $1,058,000 | -22.0% | 115,000 | 0.0% | 0.22% | -11.4% | |
| TFX | TELEFLEX INC | $1,047,000 | -4.1% | 6,500 | 0.0% | 0.21% | +8.6% | |
| LH | LABORATORY CORP AMER HLDGS | $1,027,000 | -6.6% | 8,000 | 0.0% | 0.21% | +5.5% | |
| ACHN | ACHILLION PHARMACEUTICALS IN | $991,000 | -49.0% | 240,000 | 0.0% | 0.20% | -42.2% | |
| ABBV | ABBVIE INC | $939,000 | -0.7% | 15,000 | 0.0% | 0.19% | +12.3% | |
| ALNY | ALNYLAM PHARMACEUTICALS INC | $899,000 | -44.7% | 24,000 | 0.0% | 0.18% | -37.4% | |
| MOH | MOLINA HEALTHCARE INC | $895,000 | -7.0% | 16,500 | 0.0% | 0.18% | +5.2% | |
| EXEL | EXELIXIS INC | $895,000 | +16.7% | 60,000 | 0.0% | 0.18% | +31.7% | |
| PTLA | PORTOLA PHARMACEUTICALS INC | $808,000 | -1.2% | 36,000 | 0.0% | 0.16% | +11.5% | |
| LABU | DIREXION SHS ETF TRsp biotech bl new | $788,000 | -35.8% | 25,175 | 0.0% | 0.16% | -27.5% | |
| CVS | CVS HEALTH CORP | $765,000 | -11.4% | 9,700 | 0.0% | 0.16% | +0.6% | |
| JUNO | JUNO THERAPEUTICS INC | $697,000 | -37.2% | 37,000 | 0.0% | 0.14% | -28.9% | |
| ALDR | ALDER BIOPHARMACEUTICALS INC | $686,000 | -36.5% | 33,000 | 0.0% | 0.14% | -28.2% | |
| GWPH | GW PHARMACEUTICALS PLCads | $670,000 | -15.8% | 6,000 | 0.0% | 0.14% | -4.9% | |
| DVA | DAVITA INC | $642,000 | -2.9% | 10,000 | 0.0% | 0.13% | +10.1% | |
| KITE | KITE PHARMA INC | $628,000 | -19.7% | 14,000 | 0.0% | 0.13% | -8.5% | |
| VAR | VARIAN MED SYS INC | $628,000 | -9.9% | 7,000 | 0.0% | 0.13% | +2.4% | |
| PODD | INSULET CORP | $565,000 | -8.0% | 15,000 | 0.0% | 0.12% | +4.5% | |
| CLDX | CELLDEX THERAPEUTICS INC NEW | $566,000 | -12.4% | 160,000 | 0.0% | 0.12% | -0.9% | |
| QTNT | QUOTIENT LTD | $532,000 | -38.1% | 110,000 | 0.0% | 0.11% | -29.7% | |
| ESPR | ESPERION THERAPEUTICS INC NEW | $501,000 | -9.6% | 40,000 | 0.0% | 0.10% | +3.0% | |
| RMD | RESMED INC | $496,000 | -4.2% | 8,000 | 0.0% | 0.10% | +8.5% | |
| NVAX | NOVAVAX INC | $410,000 | -39.3% | 325,000 | 0.0% | 0.08% | -31.1% | |
| WBMD | WEBMD HEALTH CORP | $367,000 | -0.3% | 7,400 | 0.0% | 0.08% | +13.6% | |
| AACH | AAC HLDGS INC | $326,000 | -58.4% | 45,000 | 0.0% | 0.07% | -52.5% | |
| PEN | PENUMBRA INC | $319,000 | -16.1% | 5,000 | 0.0% | 0.06% | -5.8% | |
| SGRY | SURGERY PARTNERS INC | $238,000 | -21.7% | 15,000 | 0.0% | 0.05% | -10.9% | |
| MYGN | MYRIAD GENETICS INC | $233,000 | -19.1% | 14,000 | 0.0% | 0.05% | -7.7% | |
| EIGR | EIGER BIOPHARMACEUTICALS INC | $39,000 | -13.3% | 3,333 | 0.0% | 0.01% | 0.0% |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- Bellevue Asset Management AG #1
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-02-10
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| IONIS PHARMACEUTICALS INC | 31 | Q3 2023 | 9.3% |
| Vertex Pharmaceuticals Incorporated | 31 | Q3 2023 | 5.9% |
| NEUROCRINE BIOSCIENCES INC | 31 | Q3 2023 | 5.7% |
| Incyte Corporation | 31 | Q3 2023 | 5.4% |
| INTUITIVE SURGICAL INC | 31 | Q3 2023 | 4.7% |
| ABBOTT LABS | 31 | Q3 2023 | 4.6% |
| ELEVANCE HEALTH INC | 31 | Q3 2023 | 4.3% |
| UnitedHealth Group Incorporated | 31 | Q3 2023 | 3.6% |
| ALNYLAM PHARMACEUTICALS INC | 31 | Q3 2023 | 3.7% |
| Boston Scientific Corporation | 31 | Q3 2023 | 2.5% |
View Bellevue Group AG's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| SC 13G | 2023-02-14 |
| SC 13G | 2023-02-14 |
View Bellevue Group AG's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.